Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rapport Therapeutics, Inc. (RAPP)
:RAPP
Holding RAPP?
Track your performance easily
RAPP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.09 - $29.74
Previous CloseN/A
Volume10.11K
Average Volume (3M)126.60K
Market Cap
$464.16M
Enterprise Value$429.97M
Total Cash (Recent Filing)$147.48M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.38
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,576,458
10 Day Avg. Volume111,838
30 Day Avg. Volume126,601
Standard Deviation0.14
R-Squared0.00
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.84
Forecast
1Y Price Target
$38.50Price Target Upside203.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Rapport Therapeutics, Inc. News
PremiumCompany Announcements
Rapport Therapeutics’ Promising Trial Results and Leadership Change
PremiumCompany Announcements
Rapport Therapeutics Reports Q3 Financials and Strategic UpdatesBulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive results from their open-label ph1 PET RO study and placebo-controlled results from their 'MAD-2' study support the dosing regimen for the ph2a PoC study of RAP-219.
Innovative BiomarkerData supports the use of a novel efficacy biomarker in the ongoing Phase II epilepsy study of RAP-219, which can predict Phase II/III success.
Top-Tier Talent AttractionRAPP should be able to attract top-tier talent, with a management team from high pedigree CNS companies like Karuna, JNJ, and Cerevel.
Bears Say
Clinical TrialsThe IND application for RAP-219 in treating diabetic peripheral neuropathic pain faces delays due to a clinical hold, impacting the progression of this key trial.
Leadership ChangeThe company's search for a new Chief Medical Officer after Bradley Galer stepped down introduces uncertainty in its leadership team.
Regulatory ChallengesThe FDA has placed a clinical hold on the Phase IIa trial of RAP-219, indicating potential regulatory hurdles for the company's drug development pipeline.
---
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $12.09 and its highest was $29.74 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Rapport Therapeutics, Inc.’s market cap is $464.16M.
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on Aug 08, 2024. The company reported -$1.7 earnings per share for the quarter, missing the consensus estimate of -$0.6 by -$1.1.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 36,576,458 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$1.7 in its last earnings report, missing expectations of -$0.6. Following the earnings report the stock price went up 2.868%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Among the largest hedge funds holding Rapport Therapeutics, Inc.’s share is Perceptive Advisors LLC. It holds Rapport Therapeutics, Inc.’s shares valued at 15M.
---
Rapport Therapeutics, Inc. Stock Smart Score
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
---
RAPP Stock 12 Month Forecast
Average Price Target
$38.50
▲(203.39% Upside)
Technical Analysis
Best Analysts Covering RAPP
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-30.60%
reiterated a buy rating 13 days ago
Copying Joseph Thome's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -30.60% per trade.
---